近日，诺和诺德发布2025年上半年财报。披露上半年公司销售以丹麦克朗计算增长16%，以固定汇率计算增长18%至1549亿丹麦克朗。经营利润以丹麦克朗计算增长25%，以固定汇率（CER）计算增长29%，至722亿丹麦克朗。糖尿病和肥胖症治疗领域销售以丹麦克朗计算增长16%，至1454亿丹麦克朗（以CER计算增长18%），增长主要由肥胖症治疗领域和GLP-1糖尿病治疗领域驱动，其中肥胖症治疗领域销售...
Source Link近日，诺和诺德发布2025年上半年财报。披露上半年公司销售以丹麦克朗计算增长16%，以固定汇率计算增长18%至1549亿丹麦克朗。经营利润以丹麦克朗计算增长25%，以固定汇率（CER）计算增长29%，至722亿丹麦克朗。糖尿病和肥胖症治疗领域销售以丹麦克朗计算增长16%，至1454亿丹麦克朗（以CER计算增长18%），增长主要由肥胖症治疗领域和GLP-1糖尿病治疗领域驱动，其中肥胖症治疗领域销售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.